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In their recent perspectives paper, Ashton and Young (2003) dis-
cuss the important issue of the therapeutic potential of selective
GABAergic treatment in affective disorders. The authors review
data available on the new antiepileptic drugs gabapentin, vigaba-
trin, tiagabine, pregabalin, topiramate, lamotrigene, amongst 
others. They conclude that this new generation of GABA enhancers
might have a therapeutic potential in some affective disorders and
chronic pain. The beneficial effects for anxiety disorders remain to
be seen. Regarding the side-effects of these compounds, the ques-
tion of the development of tolerance and dependency would be
especially important (Ashton and Young, 2003).
This prompts us to share some of our recent experiences in the
treatment of panic and anxiety using vigabatrin and tiagabine.
Initial studies by our group on the effects of vigabatrin and
tiagabine on experimentally-induced panic with cholecystokinin-
tetrapeptide (CCK-4) in healthy volunteers showed a significant
reduction of panic scores after 1 week of treatment with both com-
pounds (Zwanzger et al., 2001c; Zwanzger et al., 2003). Based on
these results, which suggested putative antipanic properties in
patients with anxiety disorders, we investigated the effects of viga-
batrin and tiagabine in patients suffering from panic disorder, with
and without agoraphobia (DSM-IV), in two small open-label trials.
Treatment with vigabatrin led to a marked reduction reduction of
anxiety on the HAMA-scale after 2 weeks and a improvement of
agoraphobia measured with the Bandelow Agoraphobia Scale.
Remission was obtained after 4 weeks of treatment. A follow-up
investigation showed that these effects could be maintained in the
following 6 months (Zwanzger et al., 2001a). In a similar trial,
treatment with tiagabine also led to a marked improvement of
panic and agoraphobia in panic disorder patients. In two out of four
patients, remission was obtained after 4 weeks (Zwanzger et al.,
2001b).
All patients were treated in the anxiety clinic and outpatient
clinic of the department of psychiatry. After the trial, follow-up
treatment was provided for all participants. During this period,
patients were seen continuously at intervals of 2–4 weeks for
approximately 1 year. Within this period, medication was tapered
off slowly over 4–6 weeks in most subjects. Psychopathology, 
possible side-effects and the development of tolerance and 
withdrawal symptoms were monitored by experienced psychia-
trists. Apart from mild dizziness or vertigo, no major side-effects
were observed in the acute phase of the study. These symptoms
most commonly were reported during the first few days of treat-
ment and after dose increase in the patients treated with tiagabine.
After treatment discontinuation, no withdrawal symptoms such as
sweating, tremor, increased blood pressure or heart rate were
observed. Similarly, there were no reports of a sudden increase of
anxiety or reoccurrence of panic attacks.
In conclusion, these initial clinical experiences in patients with
panic disorder provide further evidence that GABAergic com-
pounds might constitute an alternative treatment approach in
patients with anxiety disorders, and support the relevance of selec-
tive GABAergic compounds in the treatment of affective disorders,
as suggested by Ashton and Young (2003). Furthermore, clinical
observations after long-term treatment with both compounds do
not suggest a risk for the development of tolerance and withdraw-
al after treatment discontinuation.
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